Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Science. 2018 Nov 2;362(6414). doi: 10.1126/science.aat8407.
The pathologic accumulation and aggregation of α-synuclein (α-syn) underlies Parkinson's disease (PD). The molecular mechanisms by which pathologic α-syn causes neurodegeneration in PD are not known. Here, we found that pathologic α-syn activates poly(adenosine 5'-diphosphate-ribose) (PAR) polymerase-1 (PARP-1), and PAR generation accelerates the formation of pathologic α-syn, resulting in cell death via parthanatos. PARP inhibitors or genetic deletion of PARP-1 prevented pathologic α-syn toxicity. In a feed-forward loop, PAR converted pathologic α-syn to a more toxic strain. PAR levels were increased in the cerebrospinal fluid and brains of patients with PD, suggesting that PARP activation plays a role in PD pathogenesis. Thus, strategies aimed at inhibiting PARP-1 activation could hold promise as a disease-modifying therapy to prevent the loss of dopamine neurons in PD.
病理性α-突触核蛋白(α-syn)的积累和聚集是帕金森病(PD)的基础。病理性α-syn 导致 PD 神经退行性变的分子机制尚不清楚。在这里,我们发现病理性α-syn 激活聚(腺苷二磷酸核糖)(PAR)聚合酶 1(PARP-1),PAR 的生成加速了病理性α-syn 的形成,导致通过 parthanatos 发生细胞死亡。PARP 抑制剂或 PARP-1 的基因缺失可预防病理性α-syn 毒性。在正反馈回路中,PAR 将病理性α-syn 转化为更具毒性的菌株。PD 患者的脑脊液和大脑中 PAR 水平升高,提示 PARP 激活在 PD 发病机制中起作用。因此,旨在抑制 PARP-1 激活的策略可能有望成为一种疾病修饰疗法,以防止 PD 中多巴胺神经元的丧失。